Market Research Logo

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2015’, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Chronic Kidney Disease (Chronic Renal Failure) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Chronic Kidney Disease (Chronic Renal Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chronic Kidney Disease (Chronic Renal Failure) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Chronic Kidney Disease (Chronic Renal Failure) Overview
Therapeutics Development
Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Overview
Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Development by Companies
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Investigation by Universities/Institutes
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Chronic Kidney Disease (Chronic Renal Failure) - Products under Development by Companies
Chronic Kidney Disease (Chronic Renal Failure) - Products under Investigation by Universities/Institutes
Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development
Acceleron Pharma, Inc.
Angion Biomedica Corp.
Apceth GmbH & Co. KG
Astellas Pharma Inc.
Bayer AG
Bio-inRen
Boryung Pharmaceutical Co., Ltd.
Complexa, Inc.
Eli Lilly and Company
Evotec AG
Intercept Pharmaceuticals, Inc.
Isis Pharmaceuticals, Inc.
La Jolla Pharmaceutical Company
Lupin Limited
Nippon Zoki Pharmaceutical Co., Ltd.
OPKO Health, Inc.
Otsuka Holdings Co., Ltd.
Prismic Pharmaceuticals, Inc.
Prolong Pharmaceuticals
ProMetic Life Sciences Inc.
Reata Pharmaceuticals, Inc.
Red Glead Discovery AB
RegenMedTX, LLC
Resverlogix Corp.
Sphaera Pharma Pvt. Ltd.
Stelic Institute & Co.
Thrasos Therapeutics Inc.
Toray Industries, Inc.
VBS Pharmaceuticals
Vicore Pharma AB
Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(palmidrol + silibinin) - Drug Profile
ANG-3070 - Drug Profile
ANG-3586 - Drug Profile
ANG-4011 - Drug Profile
apabetalone - Drug Profile
APC-611 - Drug Profile
AS-2444697 - Drug Profile
ASP-6858 - Drug Profile
bardoxolone methyl - Drug Profile
BR-05001 - Drug Profile
BRN-1889 - Drug Profile
C-21 - Drug Profile
calcium succinate - Drug Profile
CAR Peptide - Drug Profile
Cardiotoxin - Drug Profile
Cell Therapy for Chronic Kidney Disease - Drug Profile
CXA-10 - Drug Profile
Drug for Kidney Diseases - Drug Profile
Drugs to Inhibit CYP24 for Secondary Hyperparathyroidism, Chronic Kidney Disease and Oncology - Drug Profile
finerenone - Drug Profile
INT-767 - Drug Profile
ISIS-FXIRx - Drug Profile
KBP-5074 - Drug Profile
LJPC-101 - Drug Profile
LY-3016859 - Drug Profile
LY-3113593 - Drug Profile
NZ-419 - Drug Profile
PBI-4050 - Drug Profile
PBI-4419 - Drug Profile
Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile
rivaroxaban - Drug Profile
Sanguinate - Drug Profile
Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism - Drug Profile
Small Molecule to Inhibit Sodium-Phosphate Cotransport for CKD and Hypertension - Drug Profile
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease - Drug Profile
Small Molecules for Chronic Kidney Disease - Drug Profile
Small Molecules for Chronic Kidney Disease - Drug Profile
Small Molecules to Inhibit SphK2 for Oncology, Kideny Disease, Autoimmune Disorders, Fibrosis and Neurodegenerative Diseases - Drug Profile
sotatercept - Drug Profile
SP-20103 - Drug Profile
SPR-494 - Drug Profile
STNM-310 - Drug Profile
Synthetic Peptides for Chronic Kidney Disease - Drug Profile
TNT-009 - Drug Profile
tolvaptan - Drug Profile
torsemide ER - Drug Profile
TRC-101 - Drug Profile
Vida-5 - Drug Profile
Chronic Kidney Disease (Chronic Renal Failure) - Recent Pipeline Updates
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products
Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2015
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Acceleron Pharma, Inc., H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp., H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Apceth GmbH & Co. KG, H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc., H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bio-inRen, H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Complexa, Inc., H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Eli Lilly and Company, H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG, H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Intercept Pharmaceuticals, Inc., H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Isis Pharmaceuticals, Inc., H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by La Jolla Pharmaceutical Company, H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Lupin Limited, H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Nippon Zoki Pharmaceutical Co., Ltd., H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OPKO Health, Inc., H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prismic Pharmaceuticals, Inc., H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prolong Pharmaceuticals, H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProMetic Life Sciences Inc., H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals, Inc., H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Red Glead Discovery AB, H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by RegenMedTX, LLC, H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp., H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Stelic Institute & Co., H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Thrasos Therapeutics Inc., H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Toray Industries, Inc., H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VBS Pharmaceuticals, H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vicore Pharma AB, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics - Recent Pipeline Updates, H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects (Contd..1), H2 2015
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2015
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report